Skip to main content
Premium Trial:

Request an Annual Quote

AACR: High-Throughput Compound Testing

Premium

At the American Association for Cancer Research's annual meeting in Chicago last week, the Novartis Institute for BioMedical Research's William Sellers spoke about the importance of finding the right combinations of drugs to treat different kinds of cancer. "One drug is never enough," he said during his talk at the opening plenary session.

Finding the right combinations can be "daunting," he added. But companies like Novartis are developing ways to make the process more efficient. Sellers showed a short clip of a high-throughput robotic system that he says can test 1,500 compounds on 600 different cancer cell lines in just three months, in order to see if these compounds have any therapeutic effect.

(Video courtesy of William Sellers)

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.